T1	CHEM 99 110	azacitidina
#1	AnnotatorNotes T1	C0004475; azacitidine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T2	CHEM 113 123	decitabina
#2	AnnotatorNotes T2	C0049065; decitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T3	DISO 149 172	leucemia mieloide aguda
#3	AnnotatorNotes T3	C0023467; Leukemia, Myelocytic, Acute; Neoplastic Process
T4	PROC 182 193	diagnóstico
#4	AnnotatorNotes T4	C0011900; Diagnosis; Diagnostic Procedure
T5	PROC 217 257	Estudio aleatorizado, doble ciego fase 3
T6	PROC 303 310	placebo
#5	AnnotatorNotes T6	C0032042; Placebos; Therapeutic or Preventive Procedure
T7	CHEM 330 341	azacitidina
#6	AnnotatorNotes T7	C0004475; azacitidine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T8	CHEM 344 354	decitabina
#7	AnnotatorNotes T8	C0049065; decitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T9	PROC 361 372	tratamiento
#8	AnnotatorNotes T9	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T10	DISO 398 421	leucemia mieloide aguda
#9	AnnotatorNotes T10	C0023467; Leukemia, Myelocytic, Acute; Neoplastic Process
T11	PROC 431 442	diagnóstico
#10	AnnotatorNotes T11	C0011900; Diagnosis; Diagnostic Procedure
T12	DISO 470 510	cáncer agresivo de las celulas mieloides
T13	ANAT 493 510	celulas mieloides
#11	AnnotatorNotes T13	C0887899; Myeloid Cells; Cell
T14	DISO 538 561	Leucemia mieloide aguda
#12	AnnotatorNotes T14	C0023467; Leukemia, Myelocytic, Acute; Neoplastic Process
T15	DISO 636 639	LMA
#13	AnnotatorNotes T15	C0023467; Leukemia, Myelocytic, Acute; Neoplastic Process
T16	PROC 647 660	diagnosticada
#14	AnnotatorNotes T16	C0011900; Diagnosis; Diagnostic Procedure
T17	PROC 1478 1484	tratar
#15	AnnotatorNotes T17	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T18	PROC 745 756	tratamiento
#16	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	CHEM 1453 1456	HMA
T20	DISO 824 853	leucemia promielocítica aguda
#17	AnnotatorNotes T20	C0023487; Acute Promyelocytic Leukemia; Neoplastic Process
T21	DISO 855 858	LPA
#18	AnnotatorNotes T21	C0023487; Acute Promyelocytic Leukemia; Neoplastic Process
T22	PROC 942 953	tratamiento
#19	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	CHEM 971 982	azacitidina
#20	AnnotatorNotes T23	C0004475; azacitidine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T24	DISO 1053 1056	LMA
#21	AnnotatorNotes T24	C0023467; Leukemia, Myelocytic, Acute; Neoplastic Process
T25	PROC 1171 1208	trasplante alogénico de células madre
#22	AnnotatorNotes T25	C2242529; Allogeneic Stem Cell Transplantation; Therapeutic or Preventive Procedure
T26	DISO 1297 1327	neoplasias mieloproliferativas
#23	AnnotatorNotes T26	C0027022; Myeloproliferative disease; Neoplastic Process
T27	DISO 1329 1351	trombocitemia esencial
#24	AnnotatorNotes T27	C0040028; Thrombocythemia, Essential; Disease or Syndrome
T28	DISO 1353 1369	policitemia vera
#25	AnnotatorNotes T28	C0032463; Polycythemia Vera; Neoplastic Process
T29	DISO 1372 1394	mielofibrosis primaria
#26	AnnotatorNotes T29	C0001815; Primary Myelofibrosis; Neoplastic Process
T30	PROC 1437 1448	tratamiento
#27	AnnotatorNotes T30	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T31	PROC 1459 1472	quimioterapia
#28	AnnotatorNotes T31	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T32	DISO 1488 1491	SMD
#29	AnnotatorNotes T32	C0026985; Myelodysplasia; Congenital Abnormality | C3463824; MYELODYSPLASTIC SYNDROME; Neoplastic Process
T33	ANAT 158 166	mieloide
#30	AnnotatorNotes T33	C0229619; Hemopoietic tissue; Tissue
T34	CHEM 261 282	vadastuximab talirine
#31	AnnotatorNotes T34	C4086942; vadastuximab talirine; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T35	ANAT 407 415	mieloide
#32	AnnotatorNotes T35	C0229619; Hemopoietic tissue; Tissue
T36	ANAT 547 555	mieloide
#33	AnnotatorNotes T36	C0229619; Hemopoietic tissue; Tissue
T37	CHEM 958 968	decitabina
#34	AnnotatorNotes T37	C0049065; decitabine; Nucleic Acid, Nucleoside, or Nucleotide · Pharmacologic Substance
T38	ANAT 1195 1208	células madre
#35	AnnotatorNotes T38	C0038250; Stem cells; Cell
T39	CHEM 46 67	Vadastuximab talirine
#36	AnnotatorNotes T39	C4086942; vadastuximab talirine; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T40	CHEM 69 78	SGN-CD33A
#37	AnnotatorNotes T40	C3827077; SGN-CD33A; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T41	CHEM 284 292	SGNCD33A
T42	Date 13 17	2015
T44	LIVB 127 144	pacientes mayores
#38	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group + C0001792; Elderly (population group); Population Group
T45	LIVB 376 393	pacientes mayores
#39	AnnotatorNotes T45	C0030705; Patients; Patient or Disabled Group + C0001792; Elderly (population group); Population Group
T47	Age 593 608	> ó = a 65 años
T48	LIVB 622 631	Pacientes
#40	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group
T49	Neg_cue 729 731	no
T50	Neg_cue 799 806	excepto
T52	LIVB 912 920	paciente
#41	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T55	LIVB 1148 1157	Pacientes
#42	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T56	LIVB 1242 1251	Pacientes
#43	AnnotatorNotes T56	C0030705; Patients; Patient or Disabled Group
T57	LIVB 1396 1405	Pacientes
#44	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T46	DISO 1110 1117	inv(16)
#45	AnnotatorNotes T46	C3897144; inv(16); Cell or Molecular Dysfunction
T51	DISO 1118 1125	t(8;21)
#46	AnnotatorNotes T51	C3897139; t(8;21); Cell or Molecular Dysfunction
T53	DISO 1127 1135	t(16;16)
#47	AnnotatorNotes T53	C4287945; t(16;16); Cell or Molecular Dysfunction
T54	DISO 1138 1146	t(15;17)
#48	AnnotatorNotes T54	C4287946; t(15;17); Cell or Molecular Dysfunction
T43	PROC 984 1000	Estado funcional
#49	AnnotatorNotes T43	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T58	PHYS 1003 1015;984 990	hematológico Estado
#50	AnnotatorNotes T58	C0221130; Hematologic function; Organ or Tissue Function (?)
T59	PROC 673 702	citológica o histológicamente
#51	AnnotatorNotes T59	C1305671; Cytology procedure; Laboratory Procedure + C0344441; Histology Procedure; Laboratory Procedure
T60	LIVB 609 620	Ambos sexos
#52	AnnotatorNotes T60	C0025266; Male population group; Population Group + C0043210; Woman; Population Group
T61	PROC 869 881	citogenetico
#53	AnnotatorNotes T61	C0752095; Cytogenetic Analysis; Molecular Biology Research Technique
A1	Population_data T44 Age
A2	Population_data T45 Age
A3	Assertion T18 Negated
A4	Assertion T20 Negated
A5	Assertion T21 Negated
A6	Status T18 History_of
A7	Status T26 History_of
A8	Status T27 History_of
A9	Status T28 History_of
A10	Status T29 History_of
A11	Status T30 History_of
A12	Status T19 History_of
A13	Status T31 History_of
A14	Status T17 History_of
#54	AnnotatorNotes T5	C0206034; Clinical Trials, Randomized; Research Activity + C0013072; Double-Blind Method; Research Activity + C0282461; Phase 3 Clinical Trials; Research Activity
R1	Combined_with Arg1:T39 Arg2:T1	
R2	Combined_with Arg1:T40 Arg2:T1	
R3	Combined_with Arg1:T39 Arg2:T2	
R4	Combined_with Arg1:T39 Arg2:T2	
R5	Experiences Arg1:T44 Arg2:T39	
R6	Experiences Arg1:T44 Arg2:T40	
R7	Experiences Arg1:T44 Arg2:T3	
R8	Location_of Arg1:T33 Arg2:T3	
T62	Quantifier_or_Qualifier 176 193	nuevo diagnóstico
#55	AnnotatorNotes T62	C1518321; Newly Diagnosed; Qualitative Concept
R9	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T62	
T63	Quantifier_or_Qualifier 425 442	nuevo diagnóstico
#56	AnnotatorNotes T63	C1518321; Newly Diagnosed; Qualitative Concept
R10	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T63	
R11	Location_of Arg1:T35 Arg2:T10	
#57	AnnotatorNotes T41	C3827077; SGN-CD33A; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
R12	Combined_with Arg1:T34 Arg2:T7	
R13	Combined_with Arg1:T41 Arg2:T7	
R14	Combined_with Arg1:T6 Arg2:T7	
R15	Combined_with Arg1:T34 Arg2:T8	
R16	Combined_with Arg1:T41 Arg2:T8	
R17	Combined_with Arg1:T6 Arg2:T8	
R18	Used_for Arg1:T34 Arg2:T9	
R19	Used_for Arg1:T41 Arg2:T9	
R20	Experiences Arg1:T45 Arg2:T34	
R21	Experiences Arg1:T45 Arg2:T41	
R22	Experiences Arg1:T45 Arg2:T6	
R23	Experiences Arg1:T45 Arg2:T10	
R24	Location_of Arg1:T13 Arg2:T12	
R25	Location_of Arg1:T36 Arg2:T14	
R26	Experiences Arg1:T48 Arg2:T15	
R27	Experiences Arg1:T48 Arg2:T59	
R29	Negation Arg1:T49 Arg2:T18	
R30	Experiences Arg1:T48 Arg2:T18	
R31	Negation Arg1:T50 Arg2:T20	
R32	Negation Arg1:T50 Arg2:T21	
R33	Experiences Arg1:T48 Arg2:T20	
R34	Experiences Arg1:T48 Arg2:T21	
T64	Quantifier_or_Qualifier 703 710	de novo
#58	AnnotatorNotes T64	C1515568; de novo; Idea or Concept
R35	Has_Quantifier_or_Qualifier Arg1:T59 Arg2:T64	
T65	Quantifier_or_Qualifier 713 723	secundaria
#59	AnnotatorNotes T65	C0175668; Secondary to; Qualitative Concept
R36	Has_Quantifier_or_Qualifier Arg1:T59 Arg2:T65	
R37	Used_for Arg1:T37 Arg2:T22	
R38	Used_for Arg1:T23 Arg2:T22	
R39	Experiences Arg1:T52 Arg2:T22	
T66	Quantifier_or_Qualifier 1016 1025	aceptable
#60	AnnotatorNotes T66	C1879533; Acceptable; Qualitative Concept
R41	Has_Quantifier_or_Qualifier Arg1:T58 Arg2:T66	
R42	Has_Quantifier_or_Qualifier Arg1:T43 Arg2:T66	
T67	CONC 862 881	Riesgo citogenetico
#61	AnnotatorNotes T67	C5419489; NCCN Cytogenetic Risk Group for ALL; Intellectual Product (?)
T68	Observation 882 892	intermedio
#62	AnnotatorNotes T68	C3640764; Intermediate Risk; Finding
T69	Observation 895 907	despaforable
#63	AnnotatorNotes T69	C0278252; Prognosis bad; Finding
R43	Has_Quantifier_or_Qualifier Arg1:T67 Arg2:T68	
R44	Has_Quantifier_or_Qualifier Arg1:T67 Arg2:T69	
R45	Overlap Arg1:T24 Arg2:T46	
R46	Overlap Arg1:T24 Arg2:T51	
R47	Overlap Arg1:T24 Arg2:T53	
R48	Overlap Arg1:T24 Arg2:T54	
R49	Experiences Arg1:T55 Arg2:T25	
T70	PROC 1229 1240	inscripción
#64	AnnotatorNotes T70	C4041024; Enrollment in clinical trial; Research Activity
R51	Before Arg1:T70 Arg2:T25	
R52	Experiences Arg1:T56 Arg2:T26	
R53	Experiences Arg1:T56 Arg2:T27	
R54	Experiences Arg1:T56 Arg2:T28	
R55	Experiences Arg1:T56 Arg2:T29	
R56	Experiences Arg1:T57 Arg2:T30	
R57	Used_for Arg1:T19 Arg2:T30	
#65	AnnotatorNotes T19	['hypomethylating agent']
R58	Experiences Arg1:T57 Arg2:T31	
R59	Experiences Arg1:T57 Arg2:T17	
R60	Experiences Arg1:T57 Arg2:T32	
T71	Observation 1068 1098	cariotipos de riesgo favorable
R61	Overlap Arg1:T24 Arg2:T71	
T72	CONC 774 797	clasificación de la OMS
R50	Used_for Arg1:T72 Arg2:T16	
#66	AnnotatorNotes R50	(?)
#67	AnnotatorNotes T72	C5204210; WHO AML Classification of Tumors; Intellectual Product
A15	Experiencer T44 Patient
A16	Experiencer T45 Patient
A17	Experiencer T60 Patient
A18	Experiencer T48 Patient
A19	Experiencer T52 Patient
A20	Experiencer T55 Patient
A21	Experiencer T56 Patient
A22	Experiencer T57 Patient
A23	Status T25 Future
